Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.62 |
| ▸ | PLK1 | P53350 | 1/20 | 0.59 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119010 | 1.00 | KMO (0.62) | KMOPLK1CAMK2DCYP19A1ABL1 | |
| SCHEMBL25178278 | 0.84 | MEN1 (0.50) | KMOPLK1CAMK2DNPC1MAPT | |
| SCHEMBL2349505 | 0.84 | KMO (0.60) | KMOPLK1CAMK2DMAP4K4IDO1 | |
| SCHEMBL28537366 | 0.82 | KMO (0.63) | KMOPLK1CAMK2DCYP19A1ABL1 | |
| SCHEMBL2406094 | 0.82 | KMO (0.59) | KMOPLK1CAMK2DCYP19A1ABL1 | |
| SCHEMBL823885 | 0.82 | HSD17B1 (0.55) | KMOPLK1CYP19A1MAP4K4 | |
| SCHEMBL2350651 | 0.82 | KMO (0.59) | KMOPLK1CAMK2DABL1BCR | |
| SCHEMBL10042675 | 0.82 | MEN1 (0.48) | KMOPLK1CAMK2DNPC1MAPT | |
| SCHEMBL5772306 | 0.82 | KMO (0.44) | KMOPLK1CAMK2DCYP19A1ABL1 | |
| SCHEMBL1466904 | 0.82 | CAMK2D (0.58) | KMOPLK1CAMK2DABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4472953-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | Nexys Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240279185-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2023150197-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | KMO 170/4885PLK1 4810/4885CAMK2D 1708/4885 |
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, NR1H4, CNR1 | KMO 488/4885PLK1 4850/4885CAMK2D 1919/4885 |
| US-20240279185-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | KMO 170/4885PLK1 4810/4885CAMK2D 1708/4885 |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | KMO 170/4885PLK1 4810/4885CAMK2D 1708/4885 |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | KMO 2770/4885PLK1 2750/4885CAMK2D 4386/4885 |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | KMO 170/4885PLK1 4810/4885CAMK2D 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.